Australia Markets closed

SNY Jan 2024 50.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
6.94+3.69 (+113.54%)
At close: 03:54PM EDT
Full screen
Previous close3.25
Open6.94
Bid5.10
Ask7.00
Strike50.00
Expiry date2024-01-19
Day's range6.94 - 6.94
Contract rangeN/A
Volume2
Open interest1.16k
  • Motley Fool

    Is Sanofi Stock a Buy Now?

    French pharmaceutical giant Sanofi (NASDAQ: SNY) has long been a leader in the market for insulin. First, Sanofi was forced to decrease the price of its most prescribed insulin product after its only two real competitors in this area did something similar. Second, Sanofi announced the acquisition of Provention Bio, a biotech focusing on developing medicines to delay or prevent the onset of autoimmune diseases, such as Type 1a diabetes.

  • Zacks

    Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

    Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

  • Zacks

    Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

    Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951